Quality
Return on invested capital, after tax
85.6% Computed
From the FY2026 filing
ValueScreener company report
Cardinal Health, Inc. (CAH)
NYSE / Healthcare / Medical - Distribution
Share price
253.71 USD Market dataClose of Oct 15, 2026Market capitalisation
58.75B USD Market dataClose of Oct 15, 2026- Market data
- Oct 15, 2026
- Filed accounts
- FY2026, filed Aug 11, 2026
- Ratios computed
- Oct 15, 2026
- Filed years
- 11, FY2016 to FY2026
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
- SEC filingFiled with the SEC
- Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
- Company statementCompany statement
- What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
- Market dataMarket data
- Prices, market value and what analysts publish, with the date they are as of.
- ComputedComputed by ValueScreener
- Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading
1 of 10
Overview
What the business is, what it costs, and how it reads on four questions.
Market dataSEC filingComputed
Four questions, at a glance
Financial strength
Current ratio
0.88 Computed
From the FY2026 filing
Valuation
Price to earnings
34.90x Computed
FY2026 accounts, priced at the latest close
Cash generation
Free cash flow yield
7.5% Computed
FY2026 accounts, priced at the latest close
Revenue and net income, as filed
- Named tests met
- 5 of 30 Which tests
The business, and the score behind its five axes
The reading, in brief
- Is it cheap
Price to earnings is 34.90x at the close of 2026-10-15 on FY2026 figures; the lines are 15.00x (Graham's defensive ceiling) and, by market convention, 10.00x, 25.00x and 40.00x, and this sits between 25.00x and 40.00x.
Today, against the Healthcare sector (223 companies), 34.90x sits at the 66th percentile; the middle half of that group runs from 13.52x to 42.98x.
- Is it good
Return on invested capital was 85.6% in FY2026, in the band labelled "Exceptional" (20.0% and above), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on the capital in the business well above the usual cost of that capital.
Today, against the Healthcare sector (233 companies), 85.6% sits at the 97th percentile; the middle half of that group runs from -37.4% to 12.8%.
- Is it safe
Interest coverage was 7.51x in FY2026, in the band labelled "Comfortable" (6.00x and above), on lines anchored on Damodaran's interest-coverage table, suggesting an interest bill operating profit covers many times over.
- Year by year against peers
- Whether Cardinal Health, Inc.'s gross margin stayed above the median of the Healthcare sector, year by year. (FY2017 to FY2025, 9 fiscal years of Cardinal Health, Inc. with a comparable figure)
- The direction
- Which way Cardinal Health, Inc.'s gross margin has moved, and how steadily. (FY2017 to FY2026, 10 filed years of Cardinal Health, Inc.)
- What could explain it
- What in Cardinal Health, Inc.'s filed statements could explain the movements. (7 readings drawn from the statement lines Cardinal Health, Inc. filed)
- What to check next
- What to check next on Cardinal Health, Inc., and where in its filings. (3 questions for Cardinal Health, Inc.)
- In one paragraph
- One paragraph on Cardinal Health, Inc.'s returns, cash, balance sheet and price. (14 of sixteen figures read for Cardinal Health, Inc.)
These are CAH’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.
Research CAHPart of Serious. New accounts start with 30 days of Professional, free, no card.
2 of 10
What changed
The newest filing, what it moved, and when the next one is due.
SEC filingCompany statement
The newest accounts on file are the FY2026 annual report: 10-K, filed Aug 11, 2026, accession 0000721371-26-000038.
3 of 10
Quality
The returns the business earns on its capital, and the margins behind them.
SEC filingComputed
| Figure | Value, source and document |
|---|---|
| Return on invested capital, after tax | 85.6% ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
Return on equityWhy n/mBook equity is zero or negative. Return on equity computed over it flips sign and can read as a strong positive on a loss-making company, so we will not show a number. | n/m ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Return on capital employed, pre-tax | 19.5% ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Return on assets | 3.0% ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Gross margin | 3.8% ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Operating margin | 1.0% ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Net margin | 0.7% ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
CAH 0.7%
0.4%2.4%
4 of 10
Financial strength
What it owes against what it owns, and whether it can meet what falls due.
SEC filingComputedCompany statement
| Figure | Value, source and document |
|---|---|
Debt to equityWhy n/mFiled shareholders equity is zero or below, so debt measured against it is not a measurement (n/m). | n/m ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Current ratio | 0.88 ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Quick ratio | 0.49 ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Interest coverage | 7.51x ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Altman Z-score | 5.13 ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Net debt | 5.28B ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
The balance sheet, line by line
Financial health
What Cardinal Health, Inc owned and owed at the end of fiscal 2026, from the balance sheet it filed (10-K, filed Aug 11, 2026, 0000721371-26-000038).
| Total assets | 57.30B FiledFY2026 10-K, filed Aug 11, 2026 |
|---|---|
| Total liabilities | 60.02B FiledFY2026 10-K, filed Aug 11, 2026 |
| Shareholders' equity | -2.88B FiledFY2026 10-K, filed Aug 11, 2026 |
| Cash | 4.86B FiledFY2026 10-K, filed Aug 11, 2026 |
| Total debt | 10.13B FiledFY2026 10-K, filed Aug 11, 2026 |
| Net debt | 5.28B |
| Current ratio | 0.88 |
| Debt to equity | n/m |
- Debt to equity: FY2026: Filed shareholders equity is zero or below, so debt measured against it is not a measurement (n/m).
Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.
5 of 10
Valuation context
What the market charges for it, against its own record and companies like it.
Market dataSEC filingComputed
| Figure | Value, source and document |
|---|---|
| Price to earnings | 34.90x ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| P/E on trailing twelve months | 34.49x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings |
Price to bookWhy n/mBook equity is zero or negative, so a ratio measured against it (debt to equity, price to book) is not a measurement, and we will not show a number. | n/m ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Price to sales | 0.24x ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Enterprise value to EBIT | 25.03x ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Enterprise value to EBITDA | 18.33x ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Price to earnings over growth | 1.23 ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Diluted earnings per share | 7.23 USD FiledFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
Graham numberWhy n/aWe do not hold this figure for this company, so there is nothing to show. | n/a ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
We publish no fair value or price target of our own. Value CAH on your own assumptions in the DCF workbench, starting from the filed figures.
Its own record, and companies like it
Valuation
What the market charges for Cardinal Health, Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.
| Share price | 253.71 USD |
|---|---|
| Market capitalisation | 58.75B USD |
| Enterprise value to EBITDA | 18.33x |
| Graham number | n/a |
| Diluted earnings per share, FY2026 | 7.23 USD |
Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since Aug 10, 2017: low 8.85x, median 24.89x, high 294.94x, latest 34.49x. 1,742 trading days with a meaningful ratio, 564 more on a loss and left out. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.
Companies like Cardinal Health, Inc
- Cencora, Inc. (COR)Market cap 65.15B USD
- Cigna Corporation (CI)Market cap 78.96B USD
- Takeda Pharmaceutical Company Limited (TAK)Market cap 61.73B USD
- McKesson Corporation (MCK)Market cap 116.40B USD
- CVS Health Corporation (CVS)Market cap 118.40B USD
Same sector (Healthcare) and size band (Large, 10B to 200B), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.
6 of 10
Cash generation
Whether profit arrives as cash, and what is paid back to shareholders.
SEC filingComputed
| Figure | Value, source and document |
|---|---|
| Free cash flow yield | 7.5% ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Free cash flow | 4.53B USD ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Free cash flow margin | 1.8% ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Dividend yield | 0.8% ComputedClose of Oct 15, 2026 · FY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Payout ratio | 28.6% ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
7 of 10
Filings
Every figure, the year it is for and the document it was read from.
SEC filingMarket data
The filed figures
Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.
| Figure | Value | Year | As of |
|---|---|---|---|
| 34.90x | FY2026 | Oct 15, 2026 | |
FormulaShare price / earnings per share. Where the filing states no earnings per share this listing can be priced on, which is every 20-F and 40-F filer because theirs is stated per ordinary share, it is market capitalisation / net income: the same multiple, undiluted. As ofThe close on Oct 15, 2026, over the filed figures of FY2026: a price is in this figure, and it moved after the filing. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itIncome statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| n/m | FY2026 | Oct 15, 2026 | |
| n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT. | |||
FormulaMarket capitalisation / shareholders equity As ofThe close on Oct 15, 2026, over the filed figures of FY2026: a price is in this figure, and it moved after the filing. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itBalance sheetFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| 25.03x | FY2026 | Oct 15, 2026 | |
Formula(Market capitalisation + total debt - cash) / operating income, or over the filing's own EBIT (income before tax + interest expense) where the filer tags no operating line, as Johnson & Johnson does not in any of its ten filed years. As ofThe close on Oct 15, 2026, over the filed figures of FY2026: a price is in this figure, and it moved after the filing. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itIncome statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tabForm10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itBalance sheetFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| 7.5% | FY2026 | Oct 15, 2026 | |
FormulaFree cash flow per share / share price x 100 As ofThe close on Oct 15, 2026, over the filed figures of FY2026: a price is in this figure, and it moved after the filing. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itCash flow statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| 85.6% | FY2026 | Aug 11, 2026 | |
FormulaVendor trailing-twelve-month return on invested capital where one is published, which uses after-tax operating profit over total assets less current liabilities. Otherwise our own recompute: NOPAT / (shareholders equity + total debt - cash) x 100, where NOPAT is the filed operating profit after tax, or the filing's own EBIT after tax where the filer tags no operating line. As ofThe filing date of the statements below, for FY2026. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itIncome statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tabForm10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itBalance sheetFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| 0.8% | FY2026 | Oct 15, 2026 | |
FormulaCommon dividends paid in the latest filed year / market capitalisation x 100. n/a where the filing cannot support it: a special or first-year payment, a total that mixes preferred dividends, or a cash-flow statement over 15 months old. As ofThe close on Oct 15, 2026, over the filed figures of FY2026: a price is in this figure, and it moved after the filing. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itCash flow statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| n/m | FY2026 | Aug 11, 2026 | |
| n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT. | |||
FormulaTotal debt / shareholders equity As ofThe filing date of the statements below, for FY2026. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itBalance sheetFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| 0.88 | FY2026 | Aug 11, 2026 | |
FormulaCurrent assets / current liabilities As ofThe filing date of the statements below, for FY2026. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itBalance sheetFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| 0.24x | FY2026 | Oct 15, 2026 | |
FormulaMarket capitalisation / revenue As ofThe close on Oct 15, 2026, over the filed figures of FY2026: a price is in this figure, and it moved after the filing. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itIncome statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| 1.23 | FY2026 | Oct 15, 2026 | |
FormulaPrice to earnings / the annual earnings growth rate, in percentage points As ofThe close on Oct 15, 2026, over the filed figures of FY2026: a price is in this figure, and it moved after the filing. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itIncome statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| 5.13 | FY2026 | Oct 15, 2026 | |
Formula1.2 x working capital/assets + 1.4 x retained earnings/assets + 3.3 x EBIT/assets + 0.6 x market value of equity/total liabilities + 1.0 x revenue/assets As ofThe close on Oct 15, 2026, over the filed figures of FY2026: a price is in this figure, and it moved after the filing. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itIncome statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tabForm10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itBalance sheetFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| -2.83 | FY2026 | Aug 11, 2026 | |
FormulaAn eight-variable index of year-on-year changes in receivables, gross margin, asset quality, revenue, depreciation, overheads, leverage and accruals As ofThe filing date of the statements below, for FY2026. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itIncome statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tabForm10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itBalance sheetFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tabForm10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itCash flow statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
| 8/9 | FY2026 | Aug 11, 2026 | |
FormulaOne point each for: positive return on assets, positive operating cash flow, rising return on assets, operating cash flow above net income, falling leverage, rising current ratio, no new shares issued, rising gross margin, rising asset turnover. As ofThe filing date of the statements below, for FY2026. Form10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itIncome statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tabForm10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itBalance sheetFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tabForm10-KFiledAug 11, 2026PeriodFY2026Accession0000721371-26-000038What we read from itCash flow statementFY2026Open on SEC.gov, accession 0000721371-26-000038, leaves this page and opens in a new tab | |||
The figures are computed from the accounts for fiscal 2026, the newest full year on file. 11 filed fiscal years on record, FY2016 to FY2026, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.
The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.
Ten years of filed figures, year by year
Ten years of filed figures
10 filed fiscal years, FY2017 to FY2026, read from the annual reports Cardinal Health, Inc filed with the SEC. Each year names its filing. Amounts in USD, as filed.
| Year | Revenue | Operating income | Net income | EPS, diluted | Free cash flow | Operating margin | Return on equity | Filing |
|---|---|---|---|---|---|---|---|---|
| FY2026 | 254.25B | 2.61B | 1.71B | 7.23 | 4.53B | 1.0% | n/m | 10-K, Aug 11, 20260000721371-26-000038 |
| FY2025 | 222.58B | 2.27B | 1.56B | 6.45 | 1.85B | 1.0% | n/m | 10-K, Aug 12, 20250000721371-25-000079 |
| FY2024 | 226.83B | 1.24B | 852.0M | 3.45 | 3.25B | 0.6% | n/m | 10-K, Aug 14, 20240000721371-24-000056 |
| FY2023 | 204.98B | 752.0M | 330.0M | 1.26 | 2.36B | 0.4% | n/m | 10-K, Aug 15, 20230000721371-23-000060 |
| FY2022 | 181.33B | -607.0M | -938.0M | -3.37 | 2.79B | -0.3% | n/m | 10-K, Aug 11, 20220000721371-22-000058 |
| FY2021 | 162.47B | 472.0M | 611.0M | 2.08 | 2.03B | 0.3% | 34.1% | 10-K, Aug 16, 20210000721371-21-000080 |
| FY2020 | 152.92B | -4.10B | -3.70B | -12.61 | 1.58B | -2.7% | -206.6% | 10-K, Aug 13, 20200000721371-20-000089 |
| FY2019 | 145.53B | 2.06B | 1.36B | 4.53 | 2.39B | 1.4% | 21.5% | 10-K, Aug 20, 20190000721371-19-000090 |
| FY2018 | 136.81B | 126.0M | 256.0M | 0.81 | 2.38B | 0.1% | 4.2% | 10-K, Aug 22, 20180000721371-18-000077 |
| FY2017 | 129.98B | 2.12B | 1.29B | 4.03 | 797.0M | 1.6% | 18.9% | 10-K, Aug 10, 20170000721371-17-000083 |
- Revenue, compound annual growth FY2017 to FY2026: 7.7%
- Earnings, compound annual growth FY2017 to FY2026: 3.2%
- Earnings per share, compound annual growth FY2017 to FY2026: 6.7%
- Free cash flow, compound annual growth FY2017 to FY2026: 21.3%
Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.
8 of 10
Risks and guardrails
The accounting screens, the published tests, and the lines you can set to be told.
ComputedCompany statement
| Figure | Value, source and document |
|---|---|
| Beneish M-score | -2.83 ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Piotroski F-score | 8/9 ComputedFY2026 10-K, filed Aug 11, 2026, 0000721371-26-000038 |
| Named tests met | 5 of 30 Computed |
| Beta | 0.33 ComputedClose of Oct 15, 2026 |
The named tests
Of 30 tests value investors published: 5 met, 18 not met, 7 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.
Which tests, by name(all 30)
- Meets
- Three forensic scores; ROIC at or above WACC; Low P/S, rising earnings (James O'Shaughnessy); Cash-covered dividend; Cash-flow yield and ROIC
- Does not
- Defensive investor (Benjamin Graham); Large cap, low P/E; Earnings yield and ROIC (Joel Greenblatt); Low PEG, low debt (Peter Lynch); Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; Dividends and buybacks; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Tangible book or below; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff)
- Not measured
- Deep value; High F-score, low P/B (Joseph Piotroski); High returns and growth; Low beta, profitable; P/E times P/B (Benjamin Graham); Book or below, low debt (Walter Schloss); Cheapest quarter on P/B (David Dreman). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(5)
- Debt to Equity: Filed shareholders equity is zero or below, so debt measured against it is not a measurement (n/m).
- P/B Ratio: Book equity is zero or negative, so a ratio measured against it (debt to equity, price to book) is not a measurement, and we will not show a number.
- Return on Equity: Book equity is zero or negative. Return on equity computed over it flips sign and can read as a strong positive on a loss-making company, so we will not show a number.
- Price To Graham: We do not hold this figure for this company, so there is nothing to show.
- Price Tangible Book: Book equity is zero or negative, so a ratio measured against it (debt to equity, price to book) is not a measurement, and we will not show a number.
9 of 10
Declared positions
Whether anybody here owns this company.
Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.
10 of 10
Next step
What to do with what you have read.
A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.
What this cannot tell you
- 5 figures could not be read on this company, among them Debt to Equity, P/B Ratio, Return on Equity. Each blank in the table above names the rest, with its reason. 7 named tests come back incomplete because of them, which is neither met nor missed.
And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.
Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.
No card. 30 free days, and nothing is charged unless you choose a plan.
ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.
A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.